Literature DB >> 1614968

Use of a pharmacokinetic model incorporating discontinuous gastrointestinal absorption to examine the occurrence of double peaks in oral concentration-time profiles.

A B Suttle1, G M Pollack, K L Brouwer.   

Abstract

Double peaks in the plasma concentration-time profile following oral administration have been reported for several compounds. A pharmacokinetic model incorporating discontinuous absorption was developed to simulate concentration-time profiles with double peaks. The gastrointestinal (GI) tract was divided into N compartments, with absorption occurring only from the second and Nth compartments. A two-compartment model was used to describe systemic drug disposition. The effect of gastric emptying and GI transit rate constants (Kl and K1, respectively), number of hypothetical gut compartments, and absorption rate constant at each site (Ka1, Ka2) on the time of occurrence of each peak (Tp1, Tp2), the theoretical fraction of the dose absorbed at each site (phi 1, phi 2), and the contribution of the second site to systemic drug exposure (expressed as phi 2rel) were examined. Simulated concentration-time profiles demonstrated that Tp2 was determined by Kt and N, while Tp1 was determined by K1 and Kt. Changes in Ka1 and Ka2 had no effect on Tp1 or Tp2. phi 1, phi 2, and phi 2rel were determined by Ka1, Ka2, and Kt, and simulations indicated that a secondary peak in the concentration-time profile will be evident only when phi 2rel is substantial. In addition, concentration-time data for ranitidine and cimetidine, which displayed double peaks, were fit with the model. The present model described both data sets well, and realistic pharmacokinetic and physiologic parameters (absorption rate constants, systemic bioavailabilities, GI residence times) were obtained.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1614968     DOI: 10.1023/a:1015890918883

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  19 in total

1.  Discontinuous oral absorption of cimetropium bromide, a new antispasmodic drug.

Authors:  B P Imbimbo; S Daniotti; A Vidi; D Foschi; F Saporiti; L Ferrante
Journal:  J Pharm Sci       Date:  1986-07       Impact factor: 3.534

2.  A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: a double-site model for drug absorption.

Authors:  Y Plusquellec; G Campistron; S Staveris; J Barre; L Jung; J P Tillement; G Houin
Journal:  J Pharmacokinet Biopharm       Date:  1987-06

3.  Scintigraphic determination of small intestinal transit time: comparison with the hydrogen breath technique.

Authors:  V J Caride; E K Prokop; F J Troncale; W Buddoura; K Winchenbach; R W McCallum
Journal:  Gastroenterology       Date:  1984-04       Impact factor: 22.682

4.  The pharmacokinetics of ranitidine in patients with chronic duodenal ulceration: a comparison of responders and non-responders.

Authors:  M L McFadyen; P I Folb; R Miller; I N Marks; M G Moshal
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function.

Authors:  D R Guay; G R Matzke; H N Bockbrader; J Dancik
Journal:  Clin Pharm       Date:  1983 Mar-Apr

6.  Measurement of gastric emptying by real-time ultrasound.

Authors:  D N Bateman; T A Whittingham
Journal:  Gut       Date:  1982-06       Impact factor: 23.059

7.  Evidence for site-specific absorption of a novel ACE inhibitor.

Authors:  G M Grass; W T Morehead
Journal:  Pharm Res       Date:  1989-09       Impact factor: 4.200

8.  Ranitidine bioavailability and kinetics in normal male subjects.

Authors:  D C Garg; D J Weidler; F N Eshelman
Journal:  Clin Pharmacol Ther       Date:  1983-04       Impact factor: 6.875

9.  Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis.

Authors:  M M Hammarlund; L K Paalzow; B Odlind
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Penicillamine kinetics in normal subjects.

Authors:  R F Bergstrom; D R Kay; T M Harkcom; J G Wagner
Journal:  Clin Pharmacol Ther       Date:  1981-09       Impact factor: 6.875

View more
  14 in total

1.  The effect of in vivo dissolution, gastric emptying rate, and intestinal transit time on the peak concentration and area-under-the-curve of drugs with different gastrointestinal permeabilities.

Authors:  L C Kaus; W R Gillespie; A S Hussain; G L Amidon
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

2.  Evidence for dissolution rate-limited absorption of COL-3, a matrix metalloproteinase inhibitor, leading to the irregular absorption profile in rats after oral administration.

Authors:  Jing Li; Hung Huynh; Eli Chan
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

3.  A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine.

Authors:  Ophelia Q P Yin; Brian Tomlinson; Albert H L Chow; Moses S S Chow
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 4.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

5.  Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations.

Authors:  Quan Zhou; Zou-Rong Ruan; Hong Yuan; Bo Jiang; Dong-Hang Xu
Journal:  World J Gastroenterol       Date:  2006-05-07       Impact factor: 5.742

6.  Applications and simulations of a discontinuous oral absorption pharmacokinetic model.

Authors:  J W Witcher; F D Boudinot
Journal:  Pharm Res       Date:  1996-11       Impact factor: 4.200

7.  The pharmacokinetics of teniloxazine in healthy subjects and patients with hepatic cirrhosis.

Authors:  R Orlando; C Benvenuti; M Mazzo; P Palatini
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

8.  In vivo evaluation of the absorption and gastrointestinal transit of avitriptan in fed and fasted subjects using gamma scintigraphy.

Authors:  P H Marathe; E P Sandefer; G E Kollia; D S Greene; R H Barbhaiya; R A Lipper; R C Page; W J Doll; U Y Ryo; G A Digenis
Journal:  J Pharmacokinet Biopharm       Date:  1998-02

9.  Gastrointestinal transit and distribution of ranitidine in the rat.

Authors:  A B Suttle; K L Brouwer
Journal:  Pharm Res       Date:  1995-09       Impact factor: 4.200

10.  Regional gastrointestinal absorption of ranitidine in the rat.

Authors:  A B Suttle; K L Brouwer
Journal:  Pharm Res       Date:  1995-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.